Title: Baclofen-induced edema in alcohol use disorders
Abstract: The Journal of Clinical PharmacologyVolume 54, Issue 4 p. 478-481 Brief Report Baclofen-induced edema in alcohol use disorders Camille Bence MD, Camille Bence MD Department of Addiction Medicine, CHU Lille, Lille cedex, France Dispositif CAMTEA, Lille cedex, FranceSearch for more papers by this authorOlivier Cottencin MD, PhD, Olivier Cottencin MD, PhD Department of Addiction Medicine, CHU Lille, Lille cedex, France Dispositif CAMTEA, Lille cedex, France Univ Lille Nord de France, Lille cedex, FranceSearch for more papers by this authorSylvie Deheul MD, Sylvie Deheul MD Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, FranceSearch for more papers by this authorSophie Gautier PharmD, PhD, Sophie Gautier PharmD, PhD Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, FranceSearch for more papers by this authorRégis Bordet MD, PhD, Régis Bordet MD, PhD Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, FranceSearch for more papers by this authorBenjamin Rolland MD, PhD, Corresponding Author Benjamin Rolland MD, PhD Department of Addiction Medicine, CHU Lille, Lille cedex, France Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, France Corresponding Author: Dr. Benjamin Rolland, Service d'Addictologie, Hôpital Fontan2, rue André Verhaeghe, CHRU de Lille, 59037 Lille cedex, France Email: [email protected]Search for more papers by this author Camille Bence MD, Camille Bence MD Department of Addiction Medicine, CHU Lille, Lille cedex, France Dispositif CAMTEA, Lille cedex, FranceSearch for more papers by this authorOlivier Cottencin MD, PhD, Olivier Cottencin MD, PhD Department of Addiction Medicine, CHU Lille, Lille cedex, France Dispositif CAMTEA, Lille cedex, France Univ Lille Nord de France, Lille cedex, FranceSearch for more papers by this authorSylvie Deheul MD, Sylvie Deheul MD Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, FranceSearch for more papers by this authorSophie Gautier PharmD, PhD, Sophie Gautier PharmD, PhD Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, FranceSearch for more papers by this authorRégis Bordet MD, PhD, Régis Bordet MD, PhD Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, FranceSearch for more papers by this authorBenjamin Rolland MD, PhD, Corresponding Author Benjamin Rolland MD, PhD Department of Addiction Medicine, CHU Lille, Lille cedex, France Dispositif CAMTEA, Lille cedex, France Department of Pharmacology and Pharmacovigilance, CHU Lille, Lille cedex, France Corresponding Author: Dr. Benjamin Rolland, Service d'Addictologie, Hôpital Fontan2, rue André Verhaeghe, CHRU de Lille, 59037 Lille cedex, France Email: [email protected]Search for more papers by this author First published: 16 November 2013 https://doi.org/10.1002/jcph.233Citations: 11Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009; 373: 2223–2233. 2 Bouza C, Angeles M, Magro A, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction. 2004; 99: 811–828. 3 Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol. 1977; 34: 422–428. 4 Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet. 2007; 370: 1915–1922. 5 Leggio L, Garbutt JC, Addolorato G, Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010; 9: 33–44. 6 Pastor A, Jones DML, Currie J. High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol. 2012; 32: 266–268. 7 Rigal L, Alexandre-Dubroeucq C, de Beaurepaire R, Le Jeunne C, Jaury P. Abstinence and “low-risk” consumption 1 year after the initiation of high-dose baclofen: A retrospective study among “high-risk” drinkers. Alcohol Alcohol. 2012; 47: 439–442. 8 Rolland B, Bordet R, Cottencin O. Alcohol-dependence: The current French craze for baclofen. Addiction. 2012; 107: 848–849. 9 Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Rapport du Comité Technique de Pharmacovigilance du 16 avril 2013 [Report from the Pharmacovigilance Technical Committee, April 6, 2013]. Available online at: http://ansm.sante.fr/content/download/52485/676187/version/2/file/CR_CT012013023_Pharmacovigilance.pdf (consulted on September 2, 2013). 10 Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239–245. 11 Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf. 2008; 31: 21–37. 12 Demers R, Heninger G. Pretibial edema and sodium retention during lithium carbonate treatment. JAMA. 1970; 214: 1845–1848. 13 Andrésdóttir MB, van Hamersvelt HW, van Helden MJ, van de Bosch WJ, Valk IM, Huysmans FT. Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: A single-centre study. J Cardiovasc Pharmacol. 2000; 35: (3 Suppl. 1): S25–S30. 14 Baclofen Official FDA information, side effects and uses. Available online at: http://www.drugs.com/pro/baclofen.html (consulted on September 2, 2013). 15 Walker SB, Chahl LA. The mechanism of enhancement of the neurogenic oedema response by baclofen. Eur J Pharmacol. 1980; 62: 27–34. 16 Chahl LA, Walker SB. The effect of baclofen on the cardiovascular system of the rat. Br J Pharmacol. 1980; 69: 631–638. 17 Shirpoor A, Salami S, Khadem-Ansari MH, Heshmatian B, Ilkhanizadeh B. Long-term ethanol consumption initiates atherosclerosis in rat aorta through inflammatory stress and endothelial dysfunction. Vascul Pharmacol. 2012; 57: 72–77. 18 Greiff L, Erjefält I, Wollmer P, Pipkorn U, Persson CG. Effects of histamine, ethanol, and a detergent on exudation and absorption across guinea pig airway mucosa in vivo. Thorax. 1991; 46: 700–705. Citing Literature Volume54, Issue4April 2014Pages 478-481 ReferencesRelatedInformation
Publication Year: 2013
Publication Date: 2013-11-16
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 13
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot